Cantor Fitzgerald launched coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with an “overweight” rating and $25 price target. The stock closed at $13.65 on March 22. Eledon is focused on developing AT-1501, which is an...
SVB Leerink launched coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with an “outperform” rating and a $34 price target. The stock closed at $14.99 on Feb. 5. Eledon is developing AT-1501, a potentially best-in-class...